MAPT and early-onset autosomal dominant Alzheimer disease: These results underscore a reduction in Tau phosphorylation within the brain, particularly in CA1 neurons, highlighting the potential of selenate as a therapeutic agent in modulating Tau pathology in Alzheimer's disease.